Vera Therapeutics VERA Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $215.26M+70.6% | $126.17M+61.3% | $78.22M+13.4% | $68.99M+207% | ||
| $100.22M+144% | $41M+72.3% | $23.79M+8.6% | $21.91M+83.8% | ||
| $315.47M+88.7% | $167.17M+63.9% | $102.01M+12.2% | $90.9M+164% | ||
| $315.47M+88.7% | $167.17M+63.9% | $102.01M+12.2% | $90.9M+164% | ||
| -$315.47M-88.7% | -$167.17M-63.9% | -$102.01M-12.2% | -$90.9M-164% | ||
| $7.53M-1.2% | $7.63M+101% | $3.79M+282% | $992K+4,860% | ||
| $24.48M+18.2% | $20.71M+160% | $7.98M+356% | $1.75M+11,567% | ||
| $15.86M+5.6% | $15.02M+149% | $6.02M+226% | $1.85M— | ||
| -$299.61M-96.9% | -$152.15M-58.5% | -$95.99M-7.8% | -$89.06M-173% | ||
| -$299.62M-96.9% | -$152.15M-58.5% | -$95.99M-7.8% | -$89.06M-173% | ||
| -$4.66-69.5% | -$2.75-20.1% | -$2.29+31.8% | -$3.36+75.8% | ||
| -$4.66-69.5% | -$2.75-20.1% | -$2.29+31.8% | -$3.36-38.3% | ||
| 255.5M+18.3% | 215.9M+27.8% | 169M+60.8% | 105.1M+131% | ||
| 255.5M+18.3% | 215.9M+27.8% | 169M+60.8% | 105.1M— | ||
| —— | —— | $251K— | —— | ||
| -$1.09M-156% | $1.93M+4.0% | $1.86M-2.1% | $1.9M— | ||
| -$315.47M-88.7% | -$167.17M-63.9% | -$102.01M-12.2% | -$90.9M-164% | ||
| -$315.01M-88.6% | -$167.07M-63.8% | -$101.99M-11.2% | -$91.75M-168% | ||
| -$315.01M-88.6% | -$167.07M-63.8% | -$101.99M-11.2% | -$91.75M-168% | ||
| -$315.47M-88.7% | -$167.17M-63.9% | -$102.01M-12.2% | -$90.9M-164% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Vera Therapeutics's income statement data come from?
- Every line is extracted from Vera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.